company background image
0HFQ logo

AnaptysBio LSE:0HFQ Stock Report

Last Price

US$21.26

Market Cap

US$564.7m

7D

-7.0%

1Y

n/a

Updated

26 Mar, 2024

Data

Company Financials +

AnaptysBio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AnaptysBio
Historical stock prices
Current Share PriceUS$21.26
52 Week HighUS$27.27
52 Week LowUS$13.80
Beta-0.27
1 Month Change-17.53%
3 Month Changen/a
1 Year Changen/a
3 Year Change0.047%
5 Year Change-70.80%
Change since IPO-80.10%

Recent News & Updates

Recent updates

Shareholder Returns

0HFQGB BiotechsGB Market
7D-7.0%2.1%2.1%
1Yn/a-29.8%3.8%

Return vs Industry: Insufficient data to determine how 0HFQ performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how 0HFQ performed against the UK Market.

Price Volatility

Is 0HFQ's price volatile compared to industry and market?
0HFQ volatility
0HFQ Average Weekly Movement12.4%
Biotechs Industry Average Movement7.8%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.2%
10% least volatile stocks in GB Market2.5%

Stable Share Price: 0HFQ's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 0HFQ's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005117Dan Fagahttps://www.anaptysbio.com

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.

AnaptysBio, Inc. Fundamentals Summary

How do AnaptysBio's earnings and revenue compare to its market cap?
0HFQ fundamental statistics
Market capUS$564.70m
Earnings (TTM)-US$163.62m
Revenue (TTM)US$17.16m

32.9x

P/S Ratio

-3.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0HFQ income statement (TTM)
RevenueUS$17.16m
Cost of RevenueUS$132.28m
Gross Profit-US$115.13m
Other ExpensesUS$48.49m
Earnings-US$163.62m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-6.11
Gross Margin-671.01%
Net Profit Margin-953.66%
Debt/Equity Ratio352.8%

How did 0HFQ perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.